Peritoneal Cancer - Pipeline Insight, 2025

DelveInsight's, "Peritoneal Cancer - Pipeline Insight, 2025" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Peritoneal Cancer: Understanding

Peritoneal Cancer: Overview

Peritoneal surface malignancy, or peritoneal cancer, refers to the infiltration of malignant cells into the serous membrane lining the abdominal cavity and organs, and is classified as either primary or secondary. Primary forms include entities like extraovarian primary peritoneal carcinoma (EOPPC) and peritoneal mesothelioma, while secondary peritoneal carcinomatosis commonly arises from gastrointestinal or gynecologic cancers. These malignancies often present with nonspecific symptoms, leading to delayed diagnosis and poor prognosis. Standard treatment includes cytoreductive surgery and intraperitoneal chemotherapy, with evolving strategies aiming to improve locoregional control and survival outcomes in this typically advanced-stage disease. Improved understanding of peritoneal tumor spread and recent advancements in therapeutic approaches offer new hope for more effective disease management. Early detection remains a challenge but is crucial for improving long-term outcomes.

As peritoneal cancer progresses, more specific symptoms may develop, reflecting the extent of disease spread. Abdominal swelling due to fluid accumulation (ascites) is common, often accompanied by discomfort or bloating. Cancer infiltration of the intestines can lead to bowel obstruction, resulting in nausea, vomiting, constipation, and abdominal pain. Urinary symptoms such as increased frequency or urgency may arise if nearby pelvic structures are affected. Patients often experience persistent fatigue and a general sense of unwellness. In advanced stages, if metastasis reaches the lungs, shortness of breath may also occur.

Peritoneal cancer arises from either primary malignancies like extraovarian primary peritoneal carcinoma (EOPPC) and malignant peritoneal mesothelioma, or secondary spread from gastrointestinal and gynecological tumors. Its pathophysiology involves tumor cell adhesion, invasion, and proliferation within the peritoneal cavity, facilitated by the unique structure of the peritoneum-comprising mesothelial and submesothelial layers rich in blood vessels, lymphatics, and immune aggregates known as milky spots. Tumor cells adhere to the peritoneal surface via molecules like CD44, ICAM-1, and VCAM-1, and penetrate through integrin-mediated interactions and matrix metalloproteinase activity. The seed and soil theory explains how the peritoneal cavity provides a favorable environment for metastasis, while genetic mutations (e.g., in BRCA1, p53, RB1) and signaling pathways involving c-MET, VEGF, and TNF-a promote tumor survival, angiogenesis, and immune evasion. Distinct tumor types, such as EOPPC via Mullerian metaplasia and desmoplastic small round cell tumors via EWSR1-WT1 fusion, demonstrate the diverse and multifaceted mechanisms driving peritoneal malignancies.

Peritoneal cancer is best treated with a multimodal approach combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). CRS removes all visible tumors, while HIPEC delivers heated chemotherapy directly into the abdominal cavity to target microscopic disease, enhancing drug effectiveness and minimizing systemic toxicity. This strategy, pioneered by Dr. Sugarbaker, has significantly improved survival in selected patients compared to traditional palliative care. Patient selection is based on factors like peritoneal cancer index (PCI), tumor histology, and overall performance status. Optimal outcomes depend on complete cytoreduction, as HIPEC penetration is limited to a few millimeters. Though effective, CRS and HIPEC carry risks of postoperative complications, requiring careful risk-benefit assessment.

"Peritoneal Cancer- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal Cancer pipeline landscape is provided which includes the disease overview and Peritoneal Cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

Peritoneal Cancer Emerging Drugs Chapters

This segment of the Peritoneal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal Cancer Emerging Drugs

• Relacorilant: Corcept Therapeutics

Relacorilant is a selective glucocorticoid receptor (GR) modulator currently under investigation for its potential role in treating various cancers, including peritoneal cancer. It works by blocking the activity of cortisol at the glucocorticoid receptor, which can help overcome cortisol-mediated resistance to chemotherapy and immunotherapy often seen in solid tumors. In peritoneal cancer, particularly high-grade serous carcinomas or cancers with peritoneal metastases, Relacorilant may enhance the efficacy of chemotherapeutic agents like nab-paclitaxel by sensitizing tumor cells to treatment. Early clinical studies have shown promising results in improving progression-free survival in certain patient populations, but further trials are ongoing to validate its safety and effectiveness in peritoneal malignancies. Currently, the drug is in Phase III stage of its development for the treatment of Peritoneal Cancer.

• Farletuzumab ecteribulin: Eisai Inc

FZEC is Eisai's first antibody drug conjugate (ADC) and that is composed of Eisai's in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the folate receptor alpha (FRa), and Eisai's in-house developed anticancer agent eribulin, using an enzymatically cleavable linker. After FZEC enters the target FRa-positive cancer cells, it is thought that the linker is enzymatically cleaved, releasing eribulin from the antibody leading to its antitumor activity. When the anticancer agent and antibody components of an ADC are separated inside a targeted antigen-positive cancer cell, it is theorized that the released anticancer agent also has a bystander effect on neighboring antigen-negative cancer cells and the component cells of the tumor microenvironment. In pre-clinical studies, FZEC demonstrated a bystander effect, with antitumor activity on the FRa-negative cancer cells surrounding the FRa-positive cancer cells. The payload eribulin was the first in the halichondrin class of microtubule dynamics inhibitor. Currently, the drug is in Phase II stage of its development for the treatment of Peritoneal Cancer.

• XMT-1660: Mersana Therapeutics

XMT-1660 is a novel DAR-6 Dolasynthen-based antibody drug conjugate carrying a DolaLock payload with controlled bystander effect and targeting B7-H4, a tumor antigen that is broadly expressed on the cell surface in breast, ovarian and endometrial cancers. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. XMT1660 is comprised of an anti-B7-H4 antibody site-specifically conjugated to Dolasynthen, with a total of 6 DolaLock Auristatin F-HPA (AF-HPA) anti-tubulin payloads per antibody (DAR-6). Currently, the drug is in Phase I stage of its development for the treatment of Peritoneal Cancer.

• AUP-55: Aurealis Therapeutics

AUP-55 is built on a non-pathogenic lactic acid bacteria Lactococcus cremoris that is genetically modified to synthetize Human Interferon Alpha (h-IFN- a), Human Interleukin 15 (h-IL-15) and Endogenous Bacterial Factors TLR2, NOD2 and TLR9. Due to the unique combination of therapeutic proteins, delivered through intra-tumoral injections, AUP-55 is able to activate the innate immune system, activate the adaptive immune system, block angiogenesis, and have a direct tumor killing effect. Currently, the drug is in Preclinical stage of its development for the treatment of Peritoneal Cancer.

Peritoneal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Peritoneal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Peritoneal Cancer
• There are approx. 60+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. Phase II include, Corcept Therapeutics.
• Phases

DelveInsight's report covers around 65+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Peritoneal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal Cancer drugs.

Peritoneal Cancer Report Insights

• Peritoneal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritoneal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peritoneal Cancer drugs?
• How many Peritoneal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritoneal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritoneal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Corcept Therapeutics
• Eisai Inc
• Mersana Therapeutics
• Aurealis Therapeutics
• K-Group, Beta, Inc.
• Regeneron Pharmaceuticals
• Toray Industries, Inc
• TORL Biotherapeutics, LLC
• Sutro Biopharma, Inc.
• Volastra Therapeutics, Inc.
• Seagen, a wholly owned subsidiary of Pfizer
• Regeneron Pharmaceuticals
• RemeGen Co., Ltd.
• Oncoinvent AS
• CanariaBio Inc.
• OncoC4, Inc.
• Numab Therapeutics AG
• Bristol-Myers Squibb
• Medicenna Therapeutics, Inc.
• MacroGenics

Key Products

• Relacorilant
• Farletuzumab ecteribulin
• XMT-1660
• AUP-55
• ZN-c3
• Ubamatamab
• TRK-950
• TORL-1-23
• STRO-002
• Sovilnesib
• SGN-B7H4V
• REGN5668
• RC88
• Radspherin
• Oregovomab
• ONC-392
• NM32-2668
• MORAb-202
• MDNA11
• Lorigerlimab